Document Type
Conference Proceeding
Publication Date
5-3-2024
Abstract
Introduction: Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a debilitating condition marked by chronic pelvic pain and concurrent lower urinary tract symptoms. Our prior research established the efficacy of Amniotic Bladder Therapy (ABT) in offering symptomatic relief to refractory IC/BPS patients for a duration of up to 3 months. This study aims to delve into the durability of ABT, examining its effects over a more extended period, specifically up to 6 months. Materials and Methods: Consecutive IC/BPS patients participated in the study, receiving intra-detrusor injections of 100mg micronized amniotic membrane. Comprehensive clinical evaluations were complemented by patient reported outcome measures, encompassing the Interstitial Cystitis Symptom Index (ICSI), Interstitial Cystitis Problem Index (ICPI), Bladder Pain/Interstitial Cystitis Symptom Score (BPIC-SS), Overactive Bladder Assessment Tool, and SF-12 Health Survey. Results: The study involved twenty-five consecutive recalcitrant IC/BPS patients, with an average age of 47.4 ± 14.4 years (29-67 years). After ABT, IC/BPS symptoms exhibited a gradual improvement up to 3 months in all patients. There was a substantial average improvement in ICSI, ICPI, and BPIC-SS scores of 72.8%, 71.9%, and 66.6%, respectively, at the 3-month mark. At the 4-month interval, seven patients experienced a resurgence of symptoms, prompting additional ABT. This secondary intervention resulted in significant improvements in IC/BPS symptoms after 2, 4, and 8 weeks. For the eighteen patients receiving a single injection, IC/BPS symptoms remained significantly reduced at 5 and 6 months compared to baseline. This persistence suggests a durable effect, as evidenced by sustained improvements in ICSI, ICPI, BPIC-SS, and OAB questionnaire scores. Conclusions: Amniotic Bladder Therapy (ABT) emerges as a promising intervention, providing enduring relief from pain and lower urinary tract symptoms for up to 6 months post-treatment in certain refractory IC/BPS patients. These findings underscore the potential of ABT as a durable and effective therapeutic option for individuals with IC/BPS unresponsive to conventional treatments.
Recommended Citation
Considine J, Radoiu C, Wittenberg S, Dhar N, Madan R, Vercnocke J, et al. [Liaw A]. Amniotic bladder therapy for treating interstitial cystitis/bladder pain syndrome: a 6 month follow up. Presented at: American College of Physicians Michigan Chapter and Society of Hospital Medicine Michigan Chapter 2024 Resident and Medical Student Day; 2024 May 3: Troy, MI
Comments
American College of Physicians Michigan Chapter and Society of Hospital Medicine Michigan Chapter 2024 Resident and Medical Student Day, May 3, 2024, Troy, MI